A group of researchers has found a new way to limit excessive immune responses, which may point in a new direction for research in and treatment of e.g. autoimmune diseases.
Researchers from Aarhus University Hospital and Aarhus University in Denmark in collaboration with researchers from Colorado in the United States have found a new way to treat the inflammation involved in chronic diseases such as psoriasis, asthma and HIV. A group of transmitter substances (cytokines) in the immune system, the so-called IL-1 family, has been shown to play an important role in many of these diseases by regulating the body’s immune responses.
Professor Charles A. Dinarello from University of Colorado Denver is also an honorary doctor at Aarhus University. He is an expert in regulation and transmission of these cytokines. He is primarily known for discovering the important cytokine IL-1(-?), which plays an important role in countless diseases. In collaboration with Charles Dinarello, the Danish researchers have investigated a more efficient way of reducing the effect of the IL-1 family and in this way improve treatment of chronic inflammatory diseases.
Previous research has often focused on blocking a single cytokine or signaling pathway at a time. However, many diseases and sequela are driven by more than one cytokine. This has caused researchers to wonder if it could be possible to block more important signaling pathways of the IL-1 family at the same time, and in this way make it possible to develop better treatments. The researchers try to find a broader anti-inflammatory treatment impacting several important cytokines at the same time, but also trying to avoid that this causes unintended side-effects.
In this study, the researchers have investigated if a receptor (IL-1R3), which is not just involved in the signaling of one but six different inflammatory cytokines in the IL-1 family, could be a possible target in the treatment of chronic inflammatory disease. Using an antibody to block the effect of IL-1R3, it was possible for the researchers to investigate the effects in both studies on cells and mice.
In this way, researchers could study some of the consequences of the blocking of this receptor on the immune system. At the same time, the researchers specifically studied the effect of blocking IL-1R3 in mice with either gout, acute allergic inflammation (asthma) or psoriasis.
– The experiments showed that it was possible to effectively block the receptor and reduce manifestation of diseases, which underlines the potentials in our new approach, says MD and PhD Jesper Falkesgaard Højen.
– Even though new questions arise as a consequences of these results, we have managed to describe a new and effective approach to block IL-1 family driven inflammation, and in this way we have possibly contributed with a new direction to study and treat chronic inflammatory conditions driven by the IL-1 family.
The Latest on: Autoimmune diseases
via Google News
The Latest on: Autoimmune diseases
- Dust at work can lead to rheumatic diseaseson April 16, 2021 at 7:52 am
If you are exposed to silica (quartz) dust at work—e.g. from working with concrete and granite—you have a greater risk of certain types of rheumatic disease. This is shown by results from Aarhus ...
- Genetic variants that impact protein binding in immune cells can cause autoimmune diseaseson April 16, 2021 at 3:17 am
Certain genetic variants that cause modified protein binding in immune cells, are also seen in those at high risk of some autoimmune diseases, new research has found.
- Genetic perturbation of PU.1 binding and chromatin looping at neutrophil enhancers associates with autoimmune diseaseon April 16, 2021 at 3:07 am
PU.1 is a master regulator of myeloid development but its role in disease-relevant neutrophils is not well known. Here, the authors look at primary neutrophils from a human population and find that ...
- Autoimmune Diseases Drugs Market 2021–Global Industry Analysis, Size, Share, Trends, Demand, Growth, Opportunities and Forecast 2026on April 16, 2021 at 12:25 am
Global "Autoimmune Diseases Drugs Market"(2021-2026) provides an all-inclusive assessment of the market and offers ...
- Classification scheme developed for newly identified multiple sclerosis-like diseaseon April 15, 2021 at 8:07 am
Researchers in the Department of Neurology at Tohoku University, which is led by professor Masashi Aoki, have developed a classification scheme for neuromyelitis optica spectrum disorder, a rare ...
- Autoimmune biotech Kyverna snags longtime Amgen exec as CMOon April 13, 2021 at 8:05 am
He was most recently head of inflammation and neuroscience in Amgen’s global medical organization and global development leader for Enbrel, a drug approved for several autoimmune diseases including ...
- Autoimmune-disease drugs may reduce vaccine response; antibody treatments ineffective vs Brazil varianton April 12, 2021 at 12:34 pm
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
- Autoimmune Disease Testing Market | 2021 Global Industry Analysis By Covid-19 Impact On Healthcare Sector, Business With Forecast To 2027on April 11, 2021 at 11:09 pm
Global ”Autoimmune Disease Testing Market“ 2020 industry research report gives Advancement strategies and plans are ...
- Autoimmune Disease Diagnosis Industry Trends Include Use Of Biosensors & Nano Biosensors For Rapid Detectionon April 8, 2021 at 8:48 am
Autoimmune Disease Diagnosis Global Market Report 2021: COVID-19 Growth And Change To 2030 The Business Research Company's Autoimmune Disease Diagnosis Global Market Report 2021: COVID-19 Growth ...
- Autoimmune Disease Diagnosis Market Size, Growth and Trends - Global Forecast To 2030on April 7, 2021 at 10:01 pm
New year new updates Our reports have been revised for market size forecasts and strategies to take on 2021 after the COVID 19 impact https www thebusinessresearchcompany com global market reports The ...
via Bing News